ELN risk stratification
Genetic risk group for AML at diagnosis: ELN 2022 for intensive therapy and ELN 2024 for less-intensive therapy, with the reasoning shown.
OPEN THE TOOL →
Free tools
Tools for haemato-oncology.
Reference tools that run in your browser. No sign-in, and nothing you enter is stored or sent.
PRISM risk score
PRISM-3 risk group for newly diagnosed AML treated with a hypomethylating agent plus venetoclax (Lachowiez et al., J Clin Oncol 2026), with every term of the score shown. An independent implementation; the authors’ own calculator is at prism-aml.com.
OPEN THE TOOL →